| Bioactivity | Satoreotide (JR11) is a SSTR2 antagonist. Satoreotide is usually conjugated with radiolabeled chelators used in neuroendocrine tumor imaing[1]. |
| Name | Satoreotide |
| CAS | 1801415-23-5 |
| Sequence | {p-Cl-Phe}-cyclo({d-Cys}-F-{d-4-amino-Phe(carbamoyl)}-KTC)-{d-Tyr}-NH2 |
| Shortening | FCFFKTCY |
| Formula | C58H72ClN15O14S2 |
| Molar Mass | 1302.87 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Krebs S, et al. Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3047-3057. |
Satoreotide
CAS: 1801415-23-5 F: C58H72ClN15O14S2 W: 1302.87
Satoreotide (JR11) is a SSTR2 antagonist. Satoreotide is usually conjugated with radiolabeled chelators used in neuroend
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.